1,721,135 research outputs found
Tailored therapies for patients affected by systemic sclerosis with primary heart involvement: The role of rituximab
Full text link
October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities
Full text link
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management
Full text linkIdentifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up
Full text linkOral acetazolamide: a possible strategy to relieve congestion in worsening heart failure?
Full text linkDevice-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
No full textHeart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart failure hospital admissions in the last years and is burdened by high mortality and poor quality of life. Providing effective management for HFpEF patients is a major unmet clinical need. Increase in left atrial pressure is the key determinant of pulmonary congestion, with consequent dyspnoea and exercise limitation. Evidence on benefits of medical treatment in HFpEF patients is limited. Thus, alternative strategies, including devices able to reduce left atrial pressure, through an interatrial communication determining a left-right shunt, were developed. This review aims to summarize evidence regarding the use of percutaneous interatrial shunting devices. These devices are safe and effective in improving hemodynamic and clinical parameters, including pulmonary capillary wedge pressure, 6-min walking distance, and New York Heart Association functional class. Data on cardiovascular mortality and re-hospitalization for heart failure are still scarce
- …
